Out of the total, 14 studies focused on the impact of CYP17A1 rs743572 polymorphism in breast cancer, 1 in bladder cancer, 2 in colorectal cancer, 2 in pancreatic cancer, 6 in prostate cancer, 1 in endometrial cancer, 1 in non-Hodgkin lymphoma, 1 in hepatocellular cancer, and 1 in non-small cell lung cancer (Table 2). This evidence concerns the gene CYP17A1 and pancreatic neoplasm.